share_log

翰森製藥:截至二零二四年十一月三十日止月份之股份發行人的證券變動月報表

HANSOH PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024

HKEX ·  Dec 3, 2024 16:00

Summary by Moomoo AI

截至2024年11月30日,翰森制药提交了最新的股本变动月报。報告顯示,公司的法定/註冊股本總額維持在200,000港元,並未發生變動。已發行股份數量同樣保持不變,總數為5,935,650,070股,無新增或減少的情況。此外,報告中提及的零息可換股債券於2021年1月22日發行,將於2026年到期,總額為5,378,000美元,並未在本月內發生變動。這些債券的轉換價為每股57.48港元,可能導致725,384股新股的發行。整體來看,翰森制藥在本月內的股本結構保持穩定,未有重大變動。
截至2024年11月30日,翰森制药提交了最新的股本变动月报。報告顯示,公司的法定/註冊股本總額維持在200,000港元,並未發生變動。已發行股份數量同樣保持不變,總數為5,935,650,070股,無新增或減少的情況。此外,報告中提及的零息可換股債券於2021年1月22日發行,將於2026年到期,總額為5,378,000美元,並未在本月內發生變動。這些債券的轉換價為每股57.48港元,可能導致725,384股新股的發行。整體來看,翰森制藥在本月內的股本結構保持穩定,未有重大變動。
As of November 30, 2024, Hansen Pharmaceuticals has filed its latest monthly statement of share capital movements. The report shows that the total authorized/registered share capital of the company remained at HK$200,000 with no change. The number of issued shares remained the same, with a total of 5,935,650,070 shares, with no additions or decreases.In addition, the Zero-Dividend Convertible Notes referred to in the report issued on January 22, 2021, will mature in 2026 totaling $5,378,000, with no change during the month. The conversion price of these bonds is HK$57.48 per share, which may result in the issuance of 725,384 new shares.Overall, Johnson Pharma's equity structure remained stable during the month with no significant changes.
As of November 30, 2024, Hansen Pharmaceuticals has filed its latest monthly statement of share capital movements. The report shows that the total authorized/registered share capital of the company remained at HK$200,000 with no change. The number of issued shares remained the same, with a total of 5,935,650,070 shares, with no additions or decreases.In addition, the Zero-Dividend Convertible Notes referred to in the report issued on January 22, 2021, will mature in 2026 totaling $5,378,000, with no change during the month. The conversion price of these bonds is HK$57.48 per share, which may result in the issuance of 725,384 new shares.Overall, Johnson Pharma's equity structure remained stable during the month with no significant changes.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more